Showing results (91-100 of 97) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
Scientific Reports|March 13, 2021
Synergistic roles of Wnt modulators R-spondin2 and R-spondin3 in craniofacial morphogenesis and dental developmentNora Alhazmi, Shannon H Carroll, Kenta Kawasaki, et al.Journal of Psychopharmacology (Oxford, England)|January 17, 2014
Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PETKhanum Ridler, Roger N Gunn, Graham E Searle, et al.Cancer Research|June 3, 2004
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinaseSridhar K Rabindran, Carolyn M Discafani, Edward C Rosfjord, et al.Journal of Medicinal Chemistry|February 18, 2005
Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activityHwei-Ru Tsou, Elsebe G Overbeek-Klumpers, William A Hallett, et al.Journal of Medicinal Chemistry|December 28, 2002
Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)Allan Wissner, Elsebe Overbeek, Marvin F Reich, et al.British Journal of Pharmacology|February 29, 2000
Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesiaG M Burgess, M N Perkins, H P Rang, et al.Journal of Alzheimer'S Disease : JAD|October 9, 2010
A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's diseaseSofia Tzimopoulou, Vincent J Cunningham, Thomas E Nichols, et al.Pageof 10